Illumina (NASDAQ:ILMN) Director Keith Meister sells 50,000 shares of stock. Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 50,000 shares of Illumina stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $227.17, for a total transaction of $11,358,500.00. Following the completion of the sale, the director owned 488,917 shares in the company, valued at $111,067,274.89. The trade was a 9.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Illumina stock down 8.2%. NASDAQ:ILMN traded down $18.54 on Thursday, hitting $208.00. 4,232,792 shares of the company's stock were exchanged, compared to its average volume of 2,195,646. The firm has a 50-day moving average price of $249.77 and a 200-day moving average price of $177.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The company has a market cap of $31.45 billion, a P/E ratio of 35.80, a price-to-earnings-growth ratio of 3.23 and a beta of 1.46. Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. The company had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. Illumina's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 EPS. As a group, analysts expect that Illumina, Inc. will post 5.43 EPS for the current fiscal year. Analyst upgrades and downgrades. Several research firms have recently commented on ILMN. Canaccord Genuity Group increased their price objective on Illumina from $205.00 to $300.00 and gave the company a "hold" rating in a report on Monday, October 19th. Sanford C. Bernstein restated a "market perform" rating and set a $215.00 target price on shares of Illumina in a report on Friday, July 31st. TD Cowen upped their price target on shares of Illumina from $210.00 to $270.00 and gave the stock a "hold" rating in a research report on Tuesday, October 13th. Royal Bank Of Canada increased their price target on shares of Illumina from $230.00 to $310.00 and gave the company an "outperform" rating in a research note on Monday, October 5th. Finally, Citigroup lifted their price objective on shares of Illumina from $113.00 to $210.00 and gave the company a "sell" rating in a research report on Monday. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $244.24. Institutional trading of Illumina. Hedge funds have recently made changes to their positions in the business. Signature Equity Partners LLC lifted its holdings in Illumina by 246.5% during the 3rd quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company's stock valued at $41,000 after purchasing an additional 106 shares during the last quarter. Fiduciary Financial Advisors acquired a new position in shares of Illumina in the second quarter valued at $26,000. MCF Advisors LLC increased its holdings in shares of Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the second quarter valued at $32,000. Finally, Rakuten Securities Inc. bought a new position in shares of Illumina in the second quarter valued at about $33,000. 89.42% of the stock is owned by institutional investors and hedge funds. Illumina company profile. Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics. The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data. Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Bench to bedside: Illumina wins Singapore's massive genomic bid. SINGAPORE - November 03, 2026 - The architecture of global healthcare is undergoing a profound structural shift, moving from reactive treatments to proactive, data-driven interventions. At the epicenter of this transformation is Singapore, a nation that has consistently leveraged its agility to pioneer next-generation commercial and technological frameworks. Today, that ambition took a monumental leap forward as Illumina, Inc. secured the international tender to provide whole-genome sequencing for the SG-INSIGHT study, Phase III of Singapore's National Precision Medicine (NPM) programme. The scale of this initiative is staggering. SG-INSIGHT aims to sequence approximately 450,000 individuals - roughly one in ten Singapore residents. But the true significance lies not just in the volume of data, but in its application. This marks the critical transition from studying the genomics of healthy volunteers to integrating sequencing directly into the public healthcare system for patients with a broad spectrum of medical conditions. For strategists watching the 2026 landscape, this is the blueprint for how precision medicine will be operationalized at a national scale. The clinical pivot: from baselines to bedside. For nearly a decade, Singapore has methodically built its genomic infrastructure. Phase I established a reference database, while Phase II - known as PRECISE-SG100K - successfully mapped the DNA of 100,000 healthy residents, creating a vital multi-ancestry Asian database. Phase III is where the theoretical meets the clinical reality. "Phase III builds on nearly a decade of precision medicine in Singapore," said Professor Patrick Tan, Executive Director of PRECISE, the central entity coordinating the NPM programme. "By extending the programme to patients across the public healthcare system, SG-INSIGHT aims to deepen understanding of how genetic, lifestyle and environmental factors are associated with health and disease. Phase III reflects Singapore's ambition to build a trusted and sustainable precision health ecosystem grounded in the needs and diversity of its population." This transition to clinical application fundamentally alters the value proposition of genomic data. By connecting genomic information with real-world health records, SG-INSIGHT is designed to support the responsible introduction of genetic screening in public healthcare. It moves the needle from academic research to tangible, preventative care pathways. Healthcare providers will be able to better understand disease progression and treatment responses, tailoring interventions to individual genetic profiles. This shift mirrors the evolution BriefGlance has seen in omnichannel retail, where siloed data streams are finally unified to create a seamless, personalized consumer experience. In healthcare, the 'consumer' is the patient, and the 'omnichannel' experience is the integration of genomic predispositions, lifestyle tracking, and clinical electronic health records. By breaking down the silos between research laboratories and primary care physicians, Singapore is building an omnichannel health ecosystem that predicts illness before it manifests. "Singapore is showing what the future of precision medicine can look like at national scale," said Jacob Thaysen, Chief Executive Officer of Illumina. "By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease, generate evidence that support more informed care decisions, and ultimately move healthcare toward earlier, more precise intervention." The architecture of an asia-pacific fortress. In an era defined by geopolitical turbulence and the aggressive "de-risking" of global supply chains, national infrastructure contracts are rarely awarded on technological merit alone. Illumina's victory in this highly competitive international tender underscores a critical lesson in modern global commerce: localized footprint is the ultimate competitive advantage. While rivals like China's BGI/MGI Tech, Element Biosciences, and PacBio offer fierce competition in the sequencing space, Illumina's entrenched presence in Singapore provided an insurmountable moat. Established in 2008, Singapore now serves as Illumina's Asia Pacific regional headquarters and one of its largest global hubs. With over 1,700 employees spanning commercial operations, manufacturing, and R&D, the company has deeply integrated itself into the local biomedical ecosystem. "For nearly two decades, Singapore has been one of Illumina's most important centres for innovation, manufacturing and talent in Asia Pacific," said Nilesh Shah, Head of Region, Asia Pacific, Illumina. "Our long-standing relationship with PRECISE represents the next chapter in that commitment - combining Singapore's leadership in precision health with Illumina's local genomic capabilities and regional expertise." The pandemic exposed the fragility of globalized medical supply chains. Today, de-risking is the dominant paradigm. Singapore's decision to award this contract to a company that manufactures the very sequencing flow cells and reagents within its own borders is a masterclass in strategic procurement. It insulates the NPM programme from the geopolitical shocks and trade embargoes that could otherwise derail a multi-year public health initiative. This is not merely a vendor-client relationship; it is a strategic partnership built on supply chain resilience. Data sovereignty and regulatory moats. As genomic data becomes a foundational asset for national health and economic competitiveness, data sovereignty has emerged as a paramount concern. The SG-INSIGHT study will generate an unprecedented volume of sensitive health information, necessitating rigorous regulatory oversight. Illumina's local facility will seek the necessary accreditation to comply with Singapore's Healthcare Services Act 2020 (HCSA). This compliance is non-negotiable. The HCSA provides a comprehensive regulatory framework ensuring quality, safety, and the strict confidentiality of patient data. By aligning its bioinformatics workflows and data storage protocols with Singapore's stringent cybersecurity and privacy laws, Illumina demonstrates its capacity to navigate complex regulatory labyrinths. "In the current geopolitical climate, nations are treating genomic data as critical sovereign infrastructure," noted one regional medtech analyst observing the tender process. "Winning a contract of this magnitude requires a vendor to prove absolute adherence to local data residency and bioethics standards. You cannot offshore the processing of a nation's genetic blueprint." This localized approach also aligns with the "Sequence Once, Analyse Repeatedly" (SOAR) concept gaining traction in precision medicine circles. By maintaining a secure, sovereign database, Singaporean healthcare providers can theoretically query a patient's genomic data throughout their lifetime, continuously updating preventative care strategies as new genetic discoveries are made. Scaling the economics of precision health. The commercial implications of the SG-INSIGHT study extend far beyond the borders of the city-state. Globally, population genomics initiatives are accelerating, from the UK Biobank to the 'All of Us' Research Program in the United States. However, Singapore's initiative is distinct in its aggressive push toward clinical integration and its focus on Asian demographics - a group historically underrepresented in global genomic databases. For Illumina, currently trading around $226.58, securing this tender reinforces its dominance in the high-throughput sequencing market. It also provides a massive proving ground for its latest innovations, such as the newly expanded BioInsight Platform, designed to accelerate genomic and multiomic breakthroughs. While the specific financial terms of the SG-INSIGHT contract remain undisclosed, the strategic value is immense. It validates the company's ability to execute at a population scale, providing a powerful case study for other nations looking to modernize their healthcare systems. As BriefGlance look toward the remainder of 2026 and beyond, the intersection of technological advancement and public health will increasingly dictate national competitiveness. Singapore's investment in SG-INSIGHT is a calculated bet that the upfront costs of sequencing ten percent of its population will be dwarfed by the long-term economic benefits of a healthier, more resilient workforce and a vastly more efficient healthcare system. For corporate strategists and healthcare policymakers alike, the message is clear: the future of medicine is personalized, data-driven, and intensely local. Topics & related. Precision Medicine Are you a relevant expert who could contribute your opinion or insights to this article? BriefGlance'd love to hear from you. BriefGlance will give you full credit for your contribution. UAID: 53697